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Abstract
Background: The global increase in multidrug resistance of Acinetobacter spp. has created widespread problems in the
treatment of patients in intensive care units (ICUs) of hospitals. To assess the sensitivity of Acinetobacter isolates to
antibiotics routinely used in ICUs, we investigated antibiotic resistance patterns and extended-spectrum b-lactamase
(ESBL) production among Acinetobacter spp. isolated from the ICU of a university hospital in Kerman, Iran.
Methods: Fifteen isolates of Acinetobacter spp. were recovered from one hundred clinical specimens collected from
the ICU of Afzalipoor Hospital in Kerman, Iran, from October 2010 to June 2011. Preliminary antibiotic sensitivity testing
was carried out using the disk-diffusion breakpoint assay, and MICs of different antibiotics were determined using the
E-test. ESBL production was detected by a double-disk synergy test and confirmed by a phenotypic confirmatory test.
Substrate hydrolysis in the presence and absence of the following inhibitors was carried out using the rapid fixed-time
method: para-chloromercuribenzoate (p-CMB), clavulanic acid, sulbactam, and NaCl.
Results: Overall, 73.3% of the isolates were resistant to imipenem (MIC range 240-128 µg/mL) and 66% to
ciprofloxacin (MIC range 240-64 ± 0.08 µg/mL). All of the isolates were fully resistant (MIC 240 µg/mL) to
piperacillin, while 93.3%, 53.3%, and 93.3% were resistant to piperacillin + tazobactam (MIC 240 µg/mL), amikacin
(MIC range 128-16 µg/mL), and cefepime (MIC range 240-60 µg/mL), respectively. The isolates were also resistant
to chloramphenicol and tetracycline: MICs of these two agents were ≥ 240 µg/mL. The test for ESBL production
was positive for only three isolates (nos. 1, 10, and 15). The rate of substrate hydrolysis was highest in the presence
of p-CMB (80.2 ± 0.02) and lowest in the presence of NaCl (2.1 ± 0.01) (P ≤ 0.05).
Conclusions: Many isolates of Acinetobacter spp. are resistant to almost all antibiotics routinely used in the ICU of
our hospital, including imipenem, ciprofloxacin, and piperacillin + tazobactam. Three isolates were ESBL producers.
The other isolates exhibited high resistance to b-lactams, but they did not produce any ESBL enzymes.
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Introduction
Acinetobacter is a genus of gram-negative bacteria
belonging to the Gammaproteobacteria. They are non-
motile, oxidase negative, highly pleomorphic and usually
occur in pairs. The genus Acinetobacter has occupied an
increasingly important position as an opportunistic
pathogen in the hospital environment. The contribution
of Acinetobacter spp. to nosocomial infection has
increased over the past three decades, and many out-
breaks of hospital infection involving Acinetobacter spp.
have been reported worldwide [1-3].
Although generally regarded as commensals of human
skin and the human respiratory tract, Acinetobacter spp.
have also been implicated as the cause of serious infectious
diseases such as pneumonia, urinary tract infections, endo-
carditis, wound infections, meningitis, and septicemia,
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involving mostly patients with impaired host defenses [2].
Acinetobacter spp. have emerged as particularly important
organisms late-onset ventilator associated pneumonia in
the in tensive care unit (ICU). This is probably related, at
least in part, to the increasingly invasive diagnostic and
therapeutic procedures used in hospital ICUs in recent
years [4-6].
Acinetobacter spp. have acquired resistance to almost
all currently available antimicrobial agents, including the
aminoglycosides, the quinolones, and broad-spectrum b-
lactams. The spectrum of antibiotic resistance of these
organisms, together with their survival capabilities,
makes them a threat in hospital environments, as docu-
mented by recurring outbreaks both in highly developed
countries and elsewhere. Most strains are resistant to
cephalosporins, while resistance to carbapenems is being
reported increasingly [7,8]. One particular attribute of
these strains is the production of extended-spectrum
beta-lactamase (ESBL) enzymes that confer resistance to
b-lactams [9]. Guillou et al. [10] screened 100 isolates of
Acinetobacter spp. and found that 81% of the strains pro-
duced two types of b-lactamases (TEM and CARB).
Acinetobacter baumannii hospital isolates produce
mainly cephalosporinase-type enzyme and are inhibited
by 25 mM of clavulanic acid but not by 1 mM EDTA or
100 mM para-chloromercuribenzoate (p-CMB). The b-
lactamases produced by Acinetobacter lwoffii ULA-501,
A. baumannii ULA-187, and A. baumannii AC-14 strains
have been purified and characterized, and their kinetic
interactions with several b-lactam molecules, including
substrates and inhibitors, have been studied in detail
[11]. Three b-lactamase enzymes were identified and
appeared to be cephalosporinase-type b-lactamases with
different acylation efficiencies (kcat/Km ratio values).
Their hydrolytic activities were inhibited by benzylpeni-
cillin, piperacillin, and cefotaxime, none of which
behaved as substrates for the enzyme. Carbenicillin was a
substrate for the b-lactamase from A. lwoffii ULA-501,
although it acted as a transient inactivator of the enzymes
produced by the two A. baumannii strains. Clavulanic
acid was unable to inactivate the three b-lactamases,
whereas sulbactam behaved as an inactivator only at a
high concentration (1 mM) that was difficult to achieve
during antibiotic therapy [11].
Kim et al. [7] studied the prevalence and diversity of car-
bapenemases among imipenem-nonsusceptible Acineto-
bacter isolates in Korea. A total of 190 imipenem-
nonsusceptible Acinetobacter isolates from 12 Korean hos-
pitals in 2007 were used to determine species, prevalence,
and antimicrobial susceptibility of OXA carbapenemase-
producing and metallo-b-lactamase-producing isolates.
blaOXA-23 -like and ISAba1-associated blaOXA-51 -like
genes were detected in 80% and 12% of 178 imipenem-
nonsusceptible Acinetobacter baumannii isolates,
respectively.
Sinha et al. [9] recovered 150 clinical isolates of Acineto-
bacter and identified them using various phenotypic tests.
Antibiotic susceptibility was determined by the standard
disk-diffusion method. Most isolates were resistant to the
antibiotics tested, including the third-generation cephalos-
porins. ESBL production was detected in 28% of the iso-
lates. In the double-disk approximation test, most of the
ESBLs in Acinetobacter isolates could be detected with
cefepime and cefotaxime.
In one study in the UK, the antimicrobial susceptibility
of Acinetobacter obtained from clinical specimens in 54
laboratories was investigated. The majority of the isolates
were found to be more resistant to cefotaxime, ceftazi-
dime, piperacillin, piperacillin + tazobactam, gentamicin,
and tetracycline than the other gram negative bacteria
[12].
Little information is available on the antibiotic resistance
of Acinetobacter spp. isolated from hospitals in Iran. Khos-
roshahi and Sharifi [13] recovered 400 isolates from ICU
patients in four university hospitals in Isfahan, Iran, of
which 15 (3.75%) belonged to A. baumannii. Antibiotic
sensitivity testing showed four (26.6%) isolates were resis-
tant to imipenem and meropenem. Similarly, Farhani et al.
[14] recovered 60 isolates of Acinetobacter spp. from Sha-
hid Beheshti Hospital in Kashan, Iran. Among these, 48
were A. baumannii, six were A. lwoffi, and six were other
Acinetobacter spp. They were resistant to amikacin, tobra-
mycin, ampicillin + sulbactam, and imipenem.
To assess the level of sensitivity to antibiotics routinely
used in the ICU of our hospital and to determine the pro-
duction of ESBLs, we investigated the antibiotic resistance
pattern and ESBL production in Acinetobacter spp. iso-




More than one hundred clinical specimens were collected
from the ICU of Afzalipoor Hospital (the main university
hospital) in the city of Kerman, Iran, from October 2010
to June 2011. The majority of the patients were hospita-
lized for 4 days, and 73% of them were on ventilator-
assisted life support. The average age of the patients was
63 ± 0.8 years. Specimens of lung aspirates, blood, or
urine were collected by a laboratory technician and trans-
ferred immediately to the Microbiology Department of the
Kerman University of Medical Sciences in sterile screw-
cap tubes containing 5 mL of tryptic soy broth (TSB) med-
ium. Prior to collection of the specimens, criteria such as
previous antimicrobial therapy, immunosuppression, and
presence of bacteremia due to other pathogens before and
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after colonization by Acinetobacter were taken into
consideration.
Bacterial identification
Isolates were identified preliminarily by the chromoso-
mal transformation assay [15] using an auxothrophic
strain of Acinetobacter calcoaceticus BD143 trpE27, and
species identification was carried out using the biochem-
ical and sugar utilization tests as described by Bouvet
and Grimont [16]. Isolates were further identified by
Gram stain, motility, characteristics on nutrient agar
and Cysteine-Lactose-Electrolyte-Deficient (CLED) agar,
catalase and oxidase tests, acidity or alkalinity in triple
sugar iron (TSI) agar slants, growth on citrate agar
slants, hemolytic patterns on blood agar, glucose oxida-
tion in Hugh and Leifson medium containing 1% glu-
cose, and ability to grow at 44°C.
Antibiotic susceptibility tests
Antibiotic sensitivity of the isolates was determined
using the Kirby-Bauer disk-diffusion breakpoint assay on
Mueller-Hinton agar using Oxoid disks (purchased from
Hi-Media, India) as recommended previously by the
Clinical and Laboratory Standards Institute (CLSI, pre-
viously called NCCLS) (2007 guidelines) [17]. MICs of
different antibiotics were determined using the E-test
(Hi-Media). Susceptibility to the following antimicrobial
agents was tested: cefotaxime, cefepime, cefazolin, cipro-
floxacin, piperacillin, piperacillin + tazobactam, ceftazi-
dime, imipenem, tetracycline, gentamicin, amikacin, and
chloramphenicol. Isolates were considered susceptible if
the MIC was ≤ 2 µg/mL and resistant if the MIC was ≥
8 µg/mL. A standard culture of A. calcoaceticus BD413
was used as sensitive bacterium at an inoculum of 1.5 ×
107CFU/mL.
Detection of ESBL
Two disk-diffusion methods were employed in this
investigation, both described previously [18]. Briefly, the
first method is based on the original double-disk stan-
dard test (DDST); isolates are examined for the expan-
sion of the cefotaxime + clavulanic acid inhibition zone
adjacent to disks containing cefotaxime alone and amox-
icillin + clavulanic acid 30 + 10 mg. In the second
method, a disk containing 30 mg of ceftazidime is
placed adjacent to a combination disk containing cefta-
zidime (30 mg) with clavulanic acid (10 mg) on sterile
Mueller-Hinton agar inoculated with ESBL-positive and
non-ESBL-producing standard cultures of Acinetobacter
isolates. An expansion of > 5 mm or 50% (according to
the manufacturer’s guidelines) indicates ESBL produc-
tion. The antibiotic disks described above were obtained
from Oxoid, Mast, and Beckton Dickinson, UK.
Substrate hydrolysis in the presence and absence of
inhibitors
In order to eliminate the possibility of false-positive ESBL
tests due to intrinsic susceptibility of is olates to b-lacta-
mase inhibitors (which could result in false-positive or
false-negative tests), the rapid fixed-time assay was used
to measure b-lactamase activity, based on the reduction
of iodine by hydrolysis of cefotaxime/ceftazidime under
an ultraviolet light spectrophotometer at 450 nm. In this
case, the cultures were centrifuged at 8,000 rpm at 4°C
for 15 minutes after overnight growth in Luria-Bertani
broth medium, and the cell pellet was washed with 0.01
M sterile phosphate buffer (pH 8.0). The suspension was
sonicated with a Lab sonic sonicator (Germany) for 15
seconds using a 50% on/off pulsed cycle. Sonication was
followed by freeze-thawing at -70°C for 10 minutes. The
sonicated cells were centrifuged at 12,000 rpm for 10
minutes and then observed microscopically to see the
disintegrated bacterial cells.
The sonicated solutions of the Acinetobacter isolates
were then diluted with 2.5 mL of 0.01 M phosphate buffer
(pH 8.0). To this preparation, 0.5 mL of 200 µg/mL sub-
strate (cefotaxime and ceftazidime) was added separately
and incubated at room temperature for 30 minutes. In
case of b-lactamase inhibitors, 0.5 mL of 0.5 mM p-CMB
(Fluka, Germany), 100 mM NaCl, 200 µg/mL sulbactam/
clavulanic acid, and 200 µg/mL cloxacillin were added to
the crude enzyme preparation 15 minutes before addition
of the substrates. The reaction was stopped by the addition
of 5 mL iodine reagent containing 0.32 N I2 and 1.2 M KI
with rapid stirring at room temperature. Absorbance was
measured at 540 nm, and the results were compared with
preparation containing the inhibitors. Simultaneously, two
blanks, one containing 3 mL phosphate buffer (pH 7.5)
and 5 mL of iodine reagent and the other containing 5 mL
of phosphate buffer (pH 7.5), were run alongside of the
tests.
Statistical analysis
All analyses were performed using SPSS, version 16.0
(SPSS Inc, Chicago, IL, USA). All P values were two-tailed;
P ≤ 0.05 was considered statistically significant. Means and




From October 2010 to June 2011, more than one hundred
specimens were collected from the ICU of Afzalipoor Hos-
pital in Kerman, Iran. From these specimens, fifteen iso-
lates were iden tified as Acinetobacter spp. by different
biochemical tests and a chromosomal transformation
assay using an auxothrophic strain of A. calcoaceticus
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BD413trpE27. The study was conducted in the ICU of
Afzalipoor Hospital in Kerman, Iran. Patients were either
admitted directly to the ICU or transferred from other
wards, namely internal medicine, surgery, obstetrics, neu-
rology, and cardiology wards. Post-operative patients
requiring ventilation were admitted to the critical care
unit, while patients with medical conditions necessitating
ventilation were admitted to the ICU.
Overall, 71% of the hospitalized patients were male and
29% were female (P ≤ 0.5). The average age of the
patients was 63 ± 0.8 years. The specimens were col-
lected from the lung, blood, and urine of the patients
hospitalized for 4 days in the ICU. A greater proportion
of Acinetobacter spp. was isolated from lung aspirates
(76%) than from urine samples (4%) from patients with
urinary sepsis. The lung aspirates were homogenized
with 5 mL 0.05 mM PIPS buffer and centrifuged at 8,000
rpm before being inoculated onto the medium.
The colonies on CLED agar were circular, smooth, con-
vex, translucent, mucoid, and nonpigmented. They were
gram-negative, encapsulated, non-spore-forming coccoba-
cilli. The lactose utilization test for all isolates was nega-
tive. The organisms were nonmotile and nonhemolytic.
Antibiotic susceptibility
The results of antibiotic susceptibility testing by the disk-
diffusion test are shown in Table 1. Isolate numbers 1, 2,
4, 5, 10, and 15 were completely resistant to antibiotics
routinely used in the ICU, while isolate no. 13 was the
only one sensitive to most of the antibiotics. The emer-
gence of resistance to imipenem, piperacillin, piperacillin
+ tazobactam, and ciprofloxacin is of particularly concern
because these antibiotics are usually reserved for severely
ill patients. The breakpoints obtained by disk-diffusion
testing were further confirmed by determination of MICs,
as shown in Table 2. For isolate numbers 1, 2, 5, 7, 9, 10,
and 15, the MICs of imipenem, piperacillin, piperacillin +
tazobactam, and ciprofloxacin were 240 µg/mL.
All of the Acinetobacter isolates were also highly resis-
tant to third-generation cephalosporins (cefotaxime and
ceftazidime), with MICs exceeding 240 µg/mL. For iso-
late number 13, the MICs of imipenem and amikacin
were each 4 µg/mL, and the MICs of ceftazidime + cefo-
taxime and ciprofloxacin were each 5 µg/mL. Figure 1 (a
and b) shows the MICs of gentamicin and amikacin for
Acinetobacter isolates 1 and 12, respectively, as deter-
mined by the E-test. The imipenem-resistant isolates
were multiresistant, but, most (46%) were sensitive to
amikacin using the CLSI breakpoint of 4µg/mL. The
important observation was the complete resistance of all
isolates when tested with the amoxicillin + clavulanic
acid combination disk (Table 2).
ESBL production
The DDST method was used to detect the production of
ESBL, and results were confirmed by the presence of a
zone of inhibition around a disk containing a combina-
tion of the cephalosporin (ceftazidime) and clavulanic
acid when compared with the zone around a disk con-
taining the cephalosporin (ceftazidime) alone. Only three
isolates (nos. 1, 10, and 15) were capable of producing
ESBL. The remaining isolates exhibited a high degree of
Table 1 Antibiotic susceptibility of Acinetobacter spp. isolated from the ICU of Afzalipoor Hospital
Acinetobacter
Isolates
CTX CPM CZ CP PIP CAZ IMP Te Gm AK PIT C
1 R R R R R R R R R R R R
2 R R R R R R R R R S R R
3 R R R S R S S R I I R R
4 R R R R R R R R R I R R
5 R R R S R R R R R I R R
6 R R R R R R S R I S R R
7 R R R R R R R R I R R I
8 R R R S R R S S R R R R
9 R R R R I R R R R I R R
10 R R R R R R R R R R R R
11 R R R S R I S R I S R R
12 R R R R R R R I S S R R
13 S R R S I S S R S S S I
14 R R R I R R R R R S R I
15 R R R R R R R R R I R R
Susceptibility was determined by the disk-diffusion breakpoint method.
CTX = cefotaxime, CPM = cefepime, CZ = cefazolin, CP = ciprofloxacin, PIP = piperacillin, PIT = piperacillin + tazobactam, CAZ = ceftazidime, IMP = imipenem, Te
= tetracycline, Gm = gentamicin, AK = amikacin, C = chloramphenicol, R = resistant, I = intermediate, S = sensitive. Sterile Muller-Hinton agar was used for
determination of antibiotic susceptibility and the inoculum concentration was 1.5 × 107
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resistance to third-generation cephalosporins but did not
produce ESBL.
Substrate hydrolysis
The rates of substrate hydrolysis and the inhibitor profiles
of b-lactamase produced by the Acinetobacter isolates
from the ICU of Afzalipoor Hospital are shown in Table 3.
The highest rate of ceftazidime and cefotaxime hydrolysis
was observed in the presence of p-CMB (80.2 ± 0.02 µM/
mL), while lowest rate was observed when NaCl (2.1 ±
0.01 µM/mL) was used as substrate (P ≤ 0.05). The rate of
substrate hydrolysis decreased in the presence of sulbac-
tam (Table 3). To eliminate the possibility of false-positive
ESBL tests due to intrinsic susceptibility of b-lactamase
inhibitors or the other mechanisms, the MIC of cefotax-
ime and ceftazidime for the ESBL-producing isolates was
measured in the presence and absence of the b-lactamase
inhibitor clavulanic acid. The MICs of ceftazidime and
cefotaxime were decreased from > 240 µg/mL to 8 µg/mL
and 4 µg/mL, respectively.
Discussion
Acinetobacter spp. are resistant to the most commonly
available antibiotics; hence, they are able to survive in the
hospital environment under hostile conditions and also to
colonize susceptible patients treated with broad-spectrum
antibiotics. They are able to survive on various surfaces
(both moist and dry) in the hospital environment [19,20].
An outbreak of Acinetobacter respiratory tract infection
resulting from incomplete disinfection of ventilator
equipment was reported by Cefai et al. [21]. In our investi-
gation, specimens were collected from the lung, blood,
and, in one case (isolate 12), urine of severely ill patients
hospitalized in the ICU for 4 days. The average of age of
the infected patients was 63 ± 0.8 years. The MICs of anti-
biotics routinely used in the ICU of our hospital indicated
the emergence of resistance in some Acinetobacter isolates
(numbers 1, 2, 5, 7, 9, 10, and 15) to almost all the antibio-
tics used, including imipenem, ciprofloxacin, and pipera-
cillin + tazobactam. These findings complicate the therapy
of infections caused by Acinetobacter spp. It has been
suggested that the overwhelming use of antibiotics, parti-
cularly fluoroquinolones (e.g., ciprofloxacin) and carbape-
nems (e.g., imipenem), has resulted in the emergence of
more resistant forms of colonizing strains [6]. ESBL was
produced by three isolates, while the remaining isolates
demonstrated no enzymatic activity. These results suggest
that intrinsic resistance to antibiotics in non-ESBL-produ-
cing isolates may be due to mutation(s) in the genome
involved in antibiotic susceptibility, resulting in high MIC
values. The important observation was the insensitivity of
the Acinetobacter isolates to amoxicillin + clavulanic acid,
despite susceptibility to ceftazidime + clavulanic acid.
In a recent study, a DDST method that combined
amoxicllin + clavulanic acid with cefepime were success-
fully detected the SHV-5 b-lactamase in a Klebsiella
pneumoniae strain that produced a plasmid-borne AmpC
enzyme [22]. In another report, the use of cefepime
increased the sensitivity of the DDST with extended-
spectrum cephalosporins for the detection of ESBLs in






CPM Gm AK Am PIT CAZ C PIP Te IMP CP
1 120 240 128 >240 >240 >240 60 >240 >240 240 >240
2 30 240 4 >240 >240 >240 >240 >240 >240 240 >240
3 10 10 4 240 30 240 >240 >240 >240 4 2
4 240 >240 16 >240 >240 >240 60 >240 >240 128 128
5 >240 >240 16 >240 240 >240 60 >240 >240 240 >240
6 30 5 4 240 120 240 120 128 >240 10 5
7 240 >240 32 >240 >240 >240 60 >240 >240 240 240
8 60 240 64 >240 5 >240 10 128 4 10 4
9 240 >240 16 240 >240 240 >240 16 >240 240 >240
10 240 >240 128 >240 >240 >240 120 >240 >240 240 >240
11 10 5 4 240 60 240 120 128 16 10 4
12 60 5 32 >240 >240 >240 120 >240 >240 128 >240
13 5 5 4 >240 30 5 10 16 >240 4 5
14 60 120 4 >240 60 >240 10 >240 >240 128 64
15 30 240 4 240 30 240 60 128 240 240 240
*MIC for each antibiotic was determined twice by the E-test on Mueller-Hinton agar, and CFU/mL was kept at 1.5 × 107.
CPM = cefepime, Gm = gentamicin, AK = amikacin, Amp = ampicillin, PIT = piperacillin + tazobactam, CAZ = ceftazidime, C = chloramphenicol, PIP = piperacillin,
Te = tetracycline, IMP = imipenem, CP = ciprofloxacin.
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enterobacteria from 16% to 61% when the disks were
applied at the standard distance of 30 mm from amoxicil-
lin + clavulanic acid and from 71% to 90% when disks
were applied at a shorter distance (20 mm) [23]. These
results suggested that the inh ibition of the activities of
the AmpC enzyme and efflux pumps might enhance the
Figure 1 MICs of gentamicin [Gm (a)] and amikacin [AK (b)] for Acinetobacter isolates as determined by the E-test. The MIC was
measured as lowest concentration of the antibiotic that inhibits the visible growth of the organism. Mueller-Hinton agar with initial CFU/mL 1.5
× 107 after 24 hours of incubation at 37°C was used as medium.
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abilities of DDST to detect ESBLs in Pseudomonas
aeruginosa.
In our study, the rate of hydrolysis of ceftazidime/cefo-
taxime was highest in the presence of p-CMB and lowest
when NaCl and clavulanic acid (200 µg/ml) were used as
substrate (P ≥0.05). The results possibly explain the
expanded zone of inhibition around the ceftazidime/cefo-
taxime + clavulanic acid disk and confirmed that the ESBL
production among the isolates was not due to the intrinsic
sensitivity of Acinetobacter isolates to b-lactamase
inhibitors.
The results of antibiotic susceptibility testing of gram-
negative bacilli strains isolated from the ICU of the Fun-
deni Clinical Institute, Bucharest, Romania [4], showed
that 80% of 19 strains of Acinetobacter spp. isolated from
nasal and pharyngeal exudates and bronchial secretions
from immune-deficient patients were highly resistant to
imipenem and were also resistant to the majority of the
antibiotics tested.
Similarly, in one study on Acinetobacter susceptibility in
Iran [24], it was found that the rates of sensitivity of the
isolates to imipenem, piperacillin + tazobactam, and Ami-
kacin were 50.7%, 50%, and 38.2%, respectively. However,
it has recently become obvious that increased expression
of chromosomal genes for efflux systems plays a major
role in multidrug resistance [25]. Lagatolla et al. [26]
reported that MICs of imipenem for the blaVIM-positive
isolates were always ≥ 64 µg/mL (range 64-512 µg/mL).
Most of the blaVIM-positive isolates (49 of 64 [76%])
exhibited a multidrug-resistant phenotype that included
all of the drugs tested (imipenem, meropenem, ceftazi-
dime, piperacillin, aztreonam, amikacin, gentamicin, tobra-
mycin, and ciprofloxacin) [26]. In one outbreak in French
hospital [27], twelve clonally related and multidrug-resis-
tant Acinetobacter baumannii isolates were recovered
during a 4-month period from 12 patients hospitalized at
the Valenciennes Hospital. Seven clonally related blaVEB-1
positive A. baumannii strains were identified in the
immediate environment of the hospitalized patients.
We found similar results in our study with isolate no. 1,
which might be a carbapenemase-producing, blaVIM-
positive isolate. Further research must be conducted to
determine the mechanism of resistance to the above
antibiotics.
Conclusions
The results of this study showed that the majority of
ICU isolates of Acinetobacter spp. were highly resistant
to the antibiotics most commonly used in the ICU set-
ting, including imipenem, ciprofloxacin, cefepime, and
piperacillin + tazobactam, all of which are already used
extensively in Iranian hospitals. Tests for ESBL produc-
tion and substrate hydrolysis by resistant strains
revealed the unique property of the ESBL (sensitivity to
cefotaxime + clavulanic acid and to ceftazidime + clavu-
lanic acid, and high rate of hydrolysis by p-CMB) pro-
duced by our isolates. These findings have important
implications for physicians, microbiologists, and hospital
administrators involved in the treatment of ICU patients
in Iran.
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CTX >240 - 80±0.04
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